ToolGen Incorporated 199800
KRX · South Korea · Health Technology
KRW 34,250.00-2,050.00 (-5.65%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ToolGen, Inc. (CEO Dr. Jong-Sang Ryu, KOSDAQ: 199800), a pioneer in CRISPR-Cas9 genome-editing technology, announced the successful inauguration of its advanced Genome-Edited Crop Field Testing Facility and the hosting of its Open Innovation Mini-Symposium at the Osong Innovation Circle in Cheongju, South Korea.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR-based Gene Editing Market size & share revenue was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach around USD 12.6 Billion by 2034, at a CAGR of 13.01% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CRISPR Therapeutics A
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.